Suppr超能文献

悬浮适应性 Vero 细胞培养工艺技术的开发,用于生产病毒疫苗。

Development of suspension adapted Vero cell culture process technology for production of viral vaccines.

机构信息

Human Health Therapeutics Research Center, National Research Council of Canada, 6100 Royalmount Ave, Montreal, Quebec H4P 2R2, Canada.

Human Health Therapeutics Research Center, National Research Council of Canada, 6100 Royalmount Ave, Montreal, Quebec H4P 2R2, Canada.

出版信息

Vaccine. 2019 Nov 8;37(47):6996-7002. doi: 10.1016/j.vaccine.2019.07.003. Epub 2019 Jul 6.

Abstract

Vero cells are considered as the most widely accepted continuous cell line by the regulatory authorities (such as WHO) for the manufacture of viral vaccines for human use. The growth of Vero cells is anchorage-dependent. Scale-up and manufacturing in adherent cultures are labor intensive and complicated. Adaptation of Vero cells to grow in suspension will simplify subcultivation and process scale-up significantly, and therefore reduce the production cost. Here we report on a successful adaptation of adherent Vero cells to grow in suspension in a serum-free and animal component-free medium (IHM03) developed in-house. The suspension adapted Vero cell cultures in IHM03 grew to similar or better maximum cell density as what was observed for the adherent Vero cells grown in commercial serum-free media and with a cell doubling time of 40-44 h. Much higher cell density (8 × 10 cells/mL) was achieved in a batch culture when three volume of the culture medium was replaced during the batch culture process. Both adherent and suspension Vero cells from various stages were tested for their authenticity using short tandem repeat analysis. Testing result indicates that all Vero cell samples had 100% concordance with the Vero DNA control sample, indicating the suspension cells maintained their genetic stability. Furthermore, suspension Vero cells at a passage number of 163 were assayed for tumorigenicity, and were not found to be tumorigenic. The viral productivity of suspension Vero cells was evaluated by using vesicular stomatitis virus (VSV) as a model. The suspension cell culture showed a better productivity of VSV than the adherent Vero cell culture. In addition, the suspension culture could be infected at higher cell densities, thus improving the volumetric virus productivity. More than one log of increase in the VSV productivity was achieved in a 3L bioreactor perfusion culture infected at a cell density of 6.8 × 10 cells/mL.

摘要

Vero 细胞被监管机构(如世界卫生组织)认为是最广泛接受的用于生产人类用病毒疫苗的连续细胞系。Vero 细胞的生长是依赖于附着的。在贴壁培养中进行放大和生产是劳动密集型且复杂的。使 Vero 细胞适应悬浮培养将显著简化传代和工艺放大,从而降低生产成本。在这里,我们报告了一种成功的方法,即将贴壁 Vero 细胞适应在无血清和无动物成分的培养基(IHM03)中生长,该培养基是内部开发的。在 IHM03 中适应悬浮生长的 Vero 细胞培养物达到了与在商业无血清培养基中生长的贴壁 Vero 细胞相似或更好的最大细胞密度,细胞倍增时间为 40-44 小时。在分批培养过程中,当培养基体积替换三次时,可在分批培养中达到更高的细胞密度(8×10 个/mL)。使用短串联重复分析对来自不同阶段的贴壁和悬浮 Vero 细胞进行真实性测试。测试结果表明,所有 Vero 细胞样本与 Vero DNA 对照样本的一致性为 100%,表明悬浮细胞保持了遗传稳定性。此外,在传代数为 163 时,对悬浮 Vero 细胞进行了致瘤性检测,未发现致瘤性。使用水疱性口炎病毒(VSV)作为模型评估悬浮 Vero 细胞的病毒产率。悬浮细胞培养物显示出比贴壁 Vero 细胞培养物更高的 VSV 产率。此外,悬浮培养物可以在更高的细胞密度下感染,从而提高体积病毒产率。在感染细胞密度为 6.8×10 个/mL 的 3L 生物反应器灌注培养中,VSV 的产率提高了一个对数级以上。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验